Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of IMVAMUNE Smallpox Vaccine Regimens
NCT00437021Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2007
- Primary completion
- Apr 2009
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JYNNEOS in smallpox (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Mean Titer of Neutralizing Antibody (MVA target), Frequency of Serious Adverse Events and 3 more. Started Apr 2007; status: completed.
02
Drugs
JYNNEOS
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00437021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00437021.